MedTrace Logo

Double Blind Study of Trp01 in Patients With Alzheimer's Disease

NCT00202124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2005-09-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether tryptophan is effective in the treatment of mild to moderate Alzheimer's Disease (AD).

Conditions

Interventions

DRUG

Tryptophan

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Donald F Weaver, MD, PhD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30
Completion
2002-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202124 on ClinicalTrials.gov